Authors

  • Нуритдинов Н.А., Агзамходжаева С.С., Пирматова Н.В., Абдуллаев А.А.

Keywords:

alkogolsiz yog’li jigar kasalligi, yurak gemodinami- kasi, LRP1, LDLR, LOX1, jigar fibrozi, oksidlovchi stress.

References

1. Aхмедов ВА, Меликов ТИ. Генетические аспекты формирования неалкогольной жировой болезни печени. Леч врач. 2019;8:28-31.

2. Al-Serri A, Anstee QM, Valenti L et al. The sod2 c47t poly- morphism influences NAFLD fibrosis severity: evidence from case-control and intrafamilial allele association studie. J Hepa- tol.2011;56(2):448-54. DOI: 10.1016/j.jhep.2011.05.029.

3. Butcovan D et al. Macrophage accumulation and angio- genesis in epicardial adipose tissue in cardiac patients with or without chronic heart failure. Appl. Sci.2020;10:5871. DOI: 10.3390/app1.

4. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol.2015;62(1S):S47-S64.

5. Doukbi E et al. Browning epicardial adipose tis- sue: friend or foe? Cells.2022;11(6):991. DOI: 10.3390/ cells110609910175871.

6. Iacobellis G, Mahabadi AA. Is epicardial fat attenu- ation a novel marker of coronary inflammation? Athero- sclerosis.2019;284:212-3. DOI: 10.1016/j.atherosclero- sis.2019.02.023.

7. Jichitu A, Bungau S, Stanescu AMA et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Patho- physiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel).2021;11(4):689. DOI:10.3390/diagnos- tics11040689.

8. Li X-L, Sui J-Q, Lu L-Let al. Gene polymorphisms associat- ed with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis.2016;15:53.

9. Lonardo A et al. Cardiovascular involvement in patients with nonalcoholic fatty liver disease. Wld J Gastroenterol.2016.

10. Mantovani A et al. Nonalcoholic fatty liver disease and in- creased risk of cardiovascular disease. J Hepatol.2020.